If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
559.00    3.00 (0.54%)
Bid:
556.50
Ask:
557.00
Spread: 0.50 (0.09%)
Market Cap: £2.47b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Director/PDMR Shareholding

22 Jun 2016 13:49

Tate & Lyle PLC

Director/PDMR Shareholding

Tate & Lyle PLC (the ‘Company’) has been informed that a grant of options and awards over the Company’s ordinary shares of 25 pence each in the capital of the Company (‘Shares’) was made today to Executive Directors and Persons Discharging Managerial Responsibilities (‘PDMR’) as detailed in the table below:

Name Role Form of award (Option/ Conditional Award) Deferred Bonus1 Conditional Share Awards programme2
Rowan Adams PDMR Option 12,897 70,000
Javed Ahmed Executive Director Option 42,742 -
Joan Braca PDMR Conditional Award 9,369 90,000
Robert Gibber PDMR Option 18,524 80,000
Nick Hampton Executive Director Option 29,368 -
Rob Luijten PDMR Option 15,289 80,000
Gabriella Parisse PDMR Conditional Award 7,993 70,000
Pierre Schoumacher PDMR Conditional Award 11,755 70,000
James Stutelberg PDMR Conditional Award 12,842 90,000

1 Options and awards for the Deferred Bonus are awarded under the Tate & Lyle Group Bonus Plan (‘GBP’) in respect of the year ended 31 March 2016. No consideration is payable for the grant or exercise of the options or awards under the GBP. Further information on the operation of the GBP is provided in the Annual Report 2016.

2 Options and awards under the Conditional Share Award programme will only vest to the extent that certain Company-based financial performance criteria are satisfied over a performance period which runs from 1 April 2016 to 31 March 2017. No consideration is payable for the grant or exercise of the options or awards. Options and awards will be subject to a 12-month deferral period and continued employment to 31 March 2018.

All the above transactions took place in London.

This notification is made in accordance with DTR 3.1.4R(1)(a) of the FCA’s Disclosure and Transparency Rules.

Lucie Gilbert

Company Secretary

22 June 2016

View source version on businesswire.com: http://www.businesswire.com/news/home/20160622005771/en/

Copyright Business Wire 2016

Date   Source Headline
15th May 202611:29 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
15th May 202611:28 amGNWForm 8.3 - TATE & LYLE PLC
15th May 202611:28 amBUSForm 8.3 - TATE & LYLE PLC
15th May 202611:25 amRNSForm 8.3 - Tate & Lyle PLC
15th May 202611:20 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
15th May 202611:09 amRNSForm 8.3 - Tate & Lyle plc
15th May 202611:06 amRNS20260514_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
15th May 202611:04 amRNS20260514_TATE & LYLE_8.5 EPT RI_UK_MLI
15th May 202610:56 amRNSForm 8.3 Tate & Lyle PLC
15th May 202610:49 amPRNForm 8.3 - Tate & Lyle PLC
15th May 202610:24 amGNWDimensional Fund Advisors Ltd. : Form 8.3 - TATE & LYLE PLC - Ordinary Shares
15th May 202610:24 amBUSDimensional Fund Advisors Ltd. : Form 8.3 - TATE & LYLE PLC - Ordinary Shares
15th May 20268:56 amRNSForm 8.5 (EPT/RI)
14th May 20264:15 pmRNSPossible 595 pence all-cash offer for Tate & Lyle
14th May 20263:25 pmRNSForm 8.3 - Tate & Lyle plc
14th May 20261:24 pmRNSDisclosure Table
14th May 20261:07 pmRNSStatement re Possible Offer for Tate & Lyle
1st May 202610:00 amRNSTotal Voting Rights
1st Apr 20264:00 pmRNSHolding(s) in Company
27th Mar 20262:00 pmRNSHolding(s) in Company
13th Mar 20264:00 pmRNSHolding(s) in Company
2nd Mar 20262:00 pmRNSHolding(s) in Company
26th Feb 20267:00 amRNSTrading Statement
23rd Feb 202610:00 amRNSHolding(s) in Company
17th Feb 202612:00 pmRNSHolding(s) in Company
21st Jan 20267:00 amRNSDirectorate change
15th Jan 20269:00 amRNSHolding(s) in Company
12th Jan 202610:00 amRNSHolding(s) in Company
7th Jan 20264:30 pmRNSDirector/PDMR Shareholding
7th Jan 20262:30 pmRNSBlock listing Interim Review
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
11th Dec 202512:18 pmRNSDirector/PDMR Shareholding
9th Dec 20259:00 amRNSHolding(s) in Company
27th Nov 202510:00 amRNSDirector/PDMR Shareholding
11th Nov 20254:30 pmRNSDirector/PDMR Shareholding
10th Nov 20252:40 pmRNSDirector Declaration
6th Nov 20257:00 amRNSHalf-year Financial Report
5th Nov 20252:15 pmRNSHolding(s) in Company
3rd Nov 20255:00 pmRNSHolding(s) in Company
29th Oct 20252:00 pmRNSHolding(s) in Company
23rd Oct 20254:15 pmRNSHolding(s) in Company
21st Oct 20253:30 pmRNSHolding(s) in Company
16th Oct 202512:00 pmRNSHolding(s) in Company
8th Oct 202512:00 pmRNSHolding(s) in Company
6th Oct 20254:30 pmRNSDirector/PDMR Shareholding
6th Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 202510:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSPre-close statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.